Angiotensin-converting enzyme 2 (ACE2) is a type one transmembrane protein, which shares approximately 60% homology with ACE. The predicted human ACE2 protein sequence consists of 805 amino acids, including an N-terminal signal peptide, a single catalytic domain, a C-terminal membrane anchor, and a short cytoplasmic tail. ACE2 catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7 involved in vasoconstriction. Recently, ACE2 has been shown to be a functional receptor for the spike glycoprotein of the human coronavirus HCoV-NL63 and the human severe acute respiratory syndrome coronaviruses, SARS-CoV and SARS-CoV-2 (COVID-19 virus). Based on recent single-cell RNA sequencing (scRNA-Seq) database, high ACE2 RNA expression was identified in type II alveolar cells (AT2) of lung, esophagus upper and stratified epithelial cells, kidney proximal tubule cells, enterocytes in ileum and colon, cholangiocyte in bile duct, myocardial cells in heart, and endothelium and vascular smooth muscle cells.

PRODUCT DETAILS

Clone: A20069I

Antibody Type: Monoclonal

Reactivity: Human

Format: Alexa Fluor 594

Host: Rat

Isotype: IgG2a, κ

Applications: IHC-P - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.